- Investopedia•8 hours ago
Pfizer's Xeljanz got marketing approval from the EC, both as a monotherapy and as a combo therapy.
- MarketWatch•11 hours ago
Vivus Inc. shares rose 4.6% in premarket trade Monday after the company said it would regain the right to commercialize and promote erectile dysfunction drug Stendra in Africa, the Middle East, Turkey ...
- Motley Fool•yesterday
Diabetes patients could have new treatment options if Merck, Pfizer, Lexicon, Sanofi, and Novo Nordisk succeed with these three promising drugs.
SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||45.25 - 45.49|
|52 Week Range||36.81 - 45.49|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||23.46|
|Dividend & Yield||1.58 (3.53%)|
|1y Target Est||N/A|